.svg){kind=small}
Where to Buy
Foy is stocked at 117 licensed dispensaries across New York, with the deepest coverage in New York, Brooklyn, Queens, Binghamton, and Farmingdale. Search by ZIP code or city below to find the closest one.
Market Insights Snapshot
Foy concentrated entirely in Edible for August 2026 with a 100.0% category share, while New York Edible rank sat at 17 and brand sales declined 15.43% year over year alongside a 13.25% month-over-month dip. Despite a 0.08% increase in average price to $23.10, overall brand sales fell 15.47% year over year, indicating volume contraction outweighing pricing and leaving the single-category footprint exposed to monthly volatility; the pattern implies reliance on Edible in New York is pressuring rank stability and growth cadence.
With Edible as the sole revenue stream, a 13.25% month-over-month slide paired with a 15.43% year-over-year drop signals mix risk rather than cross-category cushioning, while the 24‑month sales expansion of 140.57% suggests the prior uptrend has cooled under current monthly pressure. Holding rank at 17 amid these declines implies mid-pack positioning that could slip if pricing holds near +0.08% while volumes contract, so the strategic read is to diversify beyond a 100.0% Edible concentration or deepen subsegment focus within Edible to defend rank and stabilize month-over-month swings.
Competitive Landscape
Foy is ranked #17 in NY Edible in August 2026, down 2 positions from #15 year over year, and flat versus May 2026 at #17, while still trailing its peak of #14 from July 2025; in contrast, Camino advanced to #1 from #2 as its sales grew 10.5% year over year and Off Hours slipped to #2 from #1 with a 24.8% year-over-year sales decline, indicating that Foy’s stationary rank alongside competitors’ divergent momentum points to share pressure from leaders gaining rank and growth, implying that without a rank improvement of at least 2 positions Foy risks ceding visibility to faster-moving rivals.
Notable Products
Strawberry Gummy 20-Pack (100mg) posted the standout move in August 2026 with a +125% month-over-month surge to $2,337, jumping to rank 6 while CBD/THC/CBN 1:1:1 Night Time Strawberry Adaptogen Chews 20-Pack (100mg THC, 100mg CBD, 100mg CBN) fell -15% yet remained at rank 1; this juxtaposition signals trading down toward value formats even as the flagship holds the top slot. CBD/THC/CBG 1:1:1 Daytime Mango Blood Orange Chews 20-Pack (100mg CBD, 100mg THC, 100mg CBG) slipped -12% at rank 2 and CBD/THC/CBC 1:1:1 Good Mood Peach Chews 20-Pack (100mg CBD, 100mg THC, 100mg CBC) declined -14% at rank 3, while the CBD/THC/CBN 1:1:1 Night Time Sleep Strawberry Chews 4-Pack (20mg THC, 20mg CBD, 20mg CBN) dropped -28% at rank 4; the core trio losing double digits alongside a mid-tier spike implies price-sensitive demand for simpler SKUs. With seven of the top ten positions occupied by Edible products and multiple 1:1:1 formulations spanning ranks 1 through 5, concentration in multi-cannabinoid chews remains high even as a single-flavor gummy gains rank, which points to a portfolio tilt where variety-led flagships retain share while entry SKUs capture incremental volume.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
